Clinical Trial Update: A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

The trial evaluating 18F-Fluciclatide PET/CT imaging for anti-angiogenic therapy in solid tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Colorectal Cancer
• Endometrial Cancer
• Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• 18F-Fluciclatide (Fluciclatide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Colon Cancer, Lung Cancer | Phase 1, Phase 2 | Status: WITHDRAWN